Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
PLoS One ; 15(1): e0227252, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-31990911

RESUMO

Patients with multimorbidity and complex health care needs are usually vulnerable elders with several concomitant advanced chronic diseases. Our research aim was to evaluate differences in patterns of multimorbidity by gender in this population and their possible prognostic implications, measured as in-hospital mortality, 1-month readmissions, and 1-year mortality. We focused on a cohort of elderly patients with well-established multimorbidity criteria admitted to a specific unit for chronic complex-care patients. Multimorbidity criteria, the Charlson, PROFUND and Barthel indexes, and the Pfeiffer test were collected prospectively during their stays. A total of 843 patients (49.2% men) were included, with a median age of 84 [interquartile range (IQR) 79-89] years. The women were older, with greater functional dependence [Barthel index: 40 (IQR:10-65) vs. 60 (IQR: 25-90)], showed more cognitive deterioration [Pfeiffer test: 5 (IQR:1-9) vs. 1 (0-6)], and had worse scores on the PROFUND index [15 (IQR:9-18) vs. 11.5 (IQR: 6-15)], all p <0.0001, while men had greater comorbidity measured with the Charlson index [5 (IQR: 3-7) vs. 4 (IQR: 3-6); p = 0.002]. In the multimorbidity criteria scale, heart failure, autoimmune diseases, dementia, and osteoarticular diseases were more frequent in women, while ischemic heart disease, chronic respiratory diseases, and neoplasms predominated in men. In the analysis of grouped patterns, neurological and osteoarticular diseases were more frequent in females, while respiratory and cancer predominated in males. We did not find gender differences for in-hospital mortality, 1-month readmissions, or 1-year mortality. In the multivariate analysis age, the Charlson, Barthel and PROFUND indexes, along with previous admissions, were independent predictors of 1-year mortality, while gender was non-significant. The Charlson and PROFUND indexes predicted mortality during follow-up more accurately in men than in women (AUC 0.70 vs. 0.57 and 0.74 vs. 0.62, respectively), with both p<0.001. In conclusion, our study shows differing patterns of multimorbidity by gender, with greater functional impairment in women and more comorbidity in men, although without differences in the prognosis. Moreover, some of these prognostic indicators had differing accuracy for the genders in predicting mortality.


Assuntos
Multimorbidade , Múltiplas Afecções Crônicas/epidemiologia , Readmissão do Paciente/estatística & dados numéricos , Idoso , Idoso de 80 Anos ou mais , Feminino , Seguimentos , Humanos , Estimativa de Kaplan-Meier , Masculino , Prognóstico , Estudos Prospectivos , Distribuição por Sexo , Fatores Sexuais , Espanha/epidemiologia , Fatores de Tempo
2.
Contemp Clin Trials ; 64: 265-273, 2018 01.
Artigo em Inglês | MEDLINE | ID: mdl-28867396

RESUMO

Patients with complex chronic diseases usually must make multiple lifestyle changes to limit and manage their conditions. Numerous studies have shown that education alone is insufficient for engaging people in lifestyle behavior change, and that theory-based behavioral approaches also are necessary. However, even the most motivated individual may have difficulty with making lifestyle changes because of the information complexity associated with multiple behavior changes. The goal of the current Healthy Hearts and Kidneys study was to evaluate, different mobile health (mHealth)-delivered intervention approaches for engaging individuals with type 2 diabetes (T2D) and concurrent chronic kidney disease (CKD) in behavior changes. Participants were randomized to 1 of 4 groups, receiving: (1) a behavioral counseling, (2) technology-based self-monitoring to reduce information complexity, (3) combined behavioral counseling and technology-based self-monitoring, or (4) baseline advice. We will determine the impact of randomization assignment on weight loss success and 24-hour urinary excretion of sodium and phosphorus. With this report we describe the study design, methods, and approaches used to assure information security for this ongoing clinical trial. Clinical Trials.gov Identifier: NCT02276742.


Assuntos
Diabetes Mellitus Tipo 2/terapia , Comportamentos Relacionados com a Saúde , Sobrepeso/terapia , Insuficiência Renal Crônica/terapia , Telemedicina/métodos , Programas de Redução de Peso/métodos , Adulto , Idoso , Terapia Comportamental , Pressão Sanguínea , Composição Corporal , Computadores de Mão , Diabetes Mellitus Tipo 2/epidemiologia , Dieta , Exercício Físico , Feminino , Humanos , Estilo de Vida , Lipídeos/sangue , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Sobrepeso/epidemiologia , Educação de Pacientes como Assunto , Penicilina G , Fósforo na Dieta , Insuficiência Renal Crônica/epidemiologia , Projetos de Pesquisa , Autocuidado , Autoeficácia , Sódio na Dieta
3.
Repert. med. cir ; 23(1): 42-46, 2014. Fotos
Artigo em Espanhol | LILACS | ID: lil-795655

RESUMO

Establecer un protocolo para la obtención de bloques de hongos utilizando agarosa como matriz. Métodos: los hongos se incluyeron en agarosa, el proceso se estandarizó y se probaron los protocolos en horno microondas, convencional y en el procesador automático para la obtención de láminas siguiendo la técnica histológica usual. Conclusiones: el protocolo del procesador para obtener múltiples láminas es reproducible y las preparaciones permitieron la visualización fácil de los hongos con coloraciones de H&E y Gomori...


To establish a protocol to obtain fungi blocks in an agarose matrix. Methods: fungi were embedded in agarose, the process was standardized and protocols were tested using a microwave oven, a conventional oven and an automated processor to obtain slides following the usual histological technique. Conclusions: the multiple slides processor protocol is reproducible and preparations allowed easy visualization of fungi with H&E and Gomori stains. Key words: agarose cell block technique, fungi, hematoxylin and eosin, Gomori...


Assuntos
Humanos , Técnicas Citológicas , Sefarose , Fungos , Hematoxilina
4.
J Clin Oncol ; 25(25): 3877-83, 2007 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-17761973

RESUMO

PURPOSE: Aromatase inhibitors (AIs) improve survival in postmenopausal women with hormone-sensitive breast cancer, but can cause joint pain and stiffness. The purpose of the current study was to evaluate the prevalence of and identify risk factors for AI-related joint symptoms. PATIENTS AND METHODS: We performed a cross-sectional survey of consecutive postmenopausal women receiving adjuvant AI therapy for early-stage hormone-sensitive breast cancer at an urban academic breast oncology clinic. Patients completed a 25-item self-administered questionnaire assessing the presence of joint symptoms that started or worsened after initiating AIs. Multivariate regression was used to compare those with AI-related arthralgia with those who did not report symptoms, adjusting for demographic and clinical factors. RESULTS: Of 200 patients who completed the survey, 94 (47%) reported having AI-related joint pain and 88 (44%) reported AI-related joint stiffness. In multiple logistic regression analysis, being overweight (body mass index of 25 to 30 kg/m(2)) and prior tamoxifen therapy were inversely associated with AI-related joint symptoms. Patients who received taxane chemotherapy were more than four times more likely than other patients to have AI-related joint pain and stiffness (odds ratio [OR] = 4.08, 95% CI, 1.58 to 10.57 and OR = 4.76; 95% CI, 1.84 to 12.28, respectively). CONCLUSION: Our study suggests that AI-related joint symptoms are more prevalent than what has been described previously in clinical trials. The success of AI therapy depends on patients' ability to adhere to treatment recommendations; therefore, additional studies of interventions that may alleviate these symptoms are needed.


Assuntos
Inibidores da Aromatase/efeitos adversos , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/epidemiologia , Artropatias/induzido quimicamente , Artropatias/epidemiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Causalidade , Comorbidade , Estudos Transversais , Feminino , Humanos , Artropatias/terapia , Pessoa de Meia-Idade , Vigilância da População , Prevalência , Análise de Regressão
5.
J Cancer Surviv ; 1(4): 283-91, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18648963

RESUMO

INTRODUCTION: Aromatase inhibitors (AIs) have become the standard of care for the adjuvant treatment of postmenopausal, hormone-sensitive breast cancer. However, patients receiving AIs may experience joint symptoms, which may lead to early discontinuation of this effective therapy. We hypothesize that acupuncture is a safe and effective treatment for AI-induced arthralgias. METHODS: Postmenopausal women with early-stage breast cancer who had self-reported musculoskeletal pain related to adjuvant AI therapy were randomized in a crossover study to receive acupuncture twice weekly for 6 weeks followed by observation or vice-versa. The intervention included full body and auricular acupuncture, and a joint-specific point prescription. Outcome measures included the Brief Pain Inventory-Short Form (BPI-SF), Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index, the Functional Assessment of Cancer Therapy-General (FACT-G) quality of life measure, and serum levels of inflammatory markers, IL-1 beta and TNF-alpha. RESULTS: Twenty-one women were enrolled and two discontinued early. From baseline to the end of treatment, patients reported improvement in the mean BPI-SF worst pain scores (5.3 to 3.3, p = 0.01), pain severity (3.7 to 2.5, p = 0.02), and pain-related functional interference (3.1 to 1.7, p = 0.02), as well as the WOMAC function subscale and FACT-G physical well-being (p = 0.02 and 0.04, respectively). No adverse events were reported. DISCUSSION/CONCLUSIONS: In this pilot study, acupuncture reduced AI-related joint symptoms and improved functional ability and was well-tolerated. IMPLICATIONS FOR CANCER SURVIVORS: Musculoskeletal side effects are common among breast cancer survivors on adjuvant AI therapy, therefore, effective treatments are needed for symptom relief and to improve adherence to these life-saving medications.


Assuntos
Acupuntura , Inibidores da Aromatase/uso terapêutico , Neoplasias da Mama/complicações , Quimioterapia Adjuvante/efeitos adversos , Artropatias/induzido quimicamente , Artropatias/terapia , Idoso , Inibidores da Aromatase/efeitos adversos , Neoplasias da Mama/tratamento farmacológico , Emprego/estatística & dados numéricos , Feminino , Nível de Saúde , Humanos , Inflamação/fisiopatologia , Artropatias/fisiopatologia , Pessoa de Meia-Idade , Medição da Dor , Projetos Piloto , Pós-Menopausa , Grupos Raciais , Comportamento Social , Inquéritos e Questionários
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA